Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01602120 · ClinicalTrials.gov registry record · Phase 2
An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy
A Phase 2 study, sponsored by Genentech.
- Terminated
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
NCT01602120 is a Phase 2 study that was terminated before completion, run by Genentech. The registered enrollment target is 159 participants.
The verdict
NCT01602120, a Phase 2 study, was terminated before completion, sponsored by Genentech.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
Study Summary
This is a multicenter, open-label extension study of safety and tolerability of lampalizumab administered by intravitreal (ITV) injection to participants with geographic atrophy (GA) who have completed the 18-month treatment in Study CFD4870g (GX01456) (NCT01229215) or 24-week treatment in Study GX29455 (NCT02288559).
Interventions
- DRUG Lampalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2012-05-29 |
| Est. Completion | 2018-02-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01602120
The ClinicalTrials.gov registry entry for NCT01602120 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lampalizumab is the first listed.
NCT01602120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01602120 about?
NCT01602120 is a clinical study titled "An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy". This is a multicenter, open-label extension study of safety and tolerability of lampalizumab administered by intravitreal (ITV) injection to participants with geographic atrophy (GA) who have completed the 18-month treatment in Study CFD4870g (GX01456) (NCT01229215) or 24-week treatment in Study GX2...
What is the current status of trial NCT01602120?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2012-05-29. Estimated completion is 2018-02-09.
What interventions are being tested in trial NCT01602120?
The interventions under investigation include: Lampalizumab (DRUG).
Who is sponsoring clinical trial NCT01602120?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.